Foundayo vs. Wegovy: A New Rivalry in Weight-Loss Medication

The U.S. Food and Drug Administration has given the green light to Eli Lilly's weight-loss pill, Foundayo, marking a significant development in the obesity treatment market currently dominated by injectables like Novo Nordisk's Wegovy.

Foundayo, a once-daily medication, mimics the appetite-suppressing GLP-1 hormone, similar to the mechanism in Lilly's injectables. Analysts highlight its absence of dosing restrictions and ease-of-use, projecting a strong market conversion.

While Foundayo aims to capture market share with its simplicity and early approval, analysts suggest its initial volumes may take time to match Oral Wegovy. However, it holds promising potential to dominate future growth, particularly with expected Medicare access.